Reckitt Benckiser Group PLC (RB.L)
4,850.00GBp
24 May 2013
-19.00p (-0.39%)
4,869.00p
4,883.00p
4,883.00p
4,810.00p
1,167,070
1,250,596
4,958.00p
3,274.00p
RB.L
About
Overall
| Beta: | 0.37 |
| Market Cap (Mil.): | £34,876.41 |
| Shares Outstanding (Mil.): | 719.10 |
| Dividend: | 78.00 |
| Yield (%): | 2.76 |
Financials
| RB.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 19.31 | 50.91 | 42.21 |
| EPS (TTM): | 2.51 | -- | -- |
| ROI: | 21.76 | 114.79 | 80.68 |
| ROE: | 31.64 | 126.54 | 88.92 |
FDA rejects Titan drug for opioid dependence
- U.S. health regulators rejected an experimental drug to treat opioid addiction made by Titan Pharmaceuticals Inc and asked for additional data showing it works, the company said.
UPDATE 2-FDA rejects Titan drug for opioid dependence
* Titan says extremely surprised and disappointed by ruling
PRESS DIGEST - Financial Times - April 23
April 22 - Headlines Bumi shares halted amid payments concern () Bribery probe lifts Walmart directors' pay ()
Severe U.S. flu season helps Reckitt top forecasts
LONDON - A severe U.S. cold and flu season helped Reckitt Benckiser , the maker of Strepsils lozenges and Mucinex decongestant, to beat first-quarter revenue expectations.
UPDATE 1-Severe U.S. flu season helps Reckitt top forecasts
* Growth driven by U.S. flu season, Dettol and Lysol sales
Reckitt benefits from flu season to begin 2013 strongly
LONDON - Reckitt Benckiser reported a strong start to 2013 as the maker of Strepsils lozenges and Mucinex decongestant continued to benefit from a severe United States cold and flu season.
Reckitt benefits from flu season to begin 2013 strongly
LONDON, April 22 - Reckitt Benckiser reported a strong start to 2013 as the maker of Strepsils lozenges and Mucinex decongestant continued to benefit from a severe United States cold and flu season.
BRIEF-Reckitt Benckiser posts 6 pct growth ex-RBP in Q1
LONDON, April 22 - Reckitt Benckiser Group PLC : * Q1 total net revenue 2,517 million STG * Q1 growth (ex rbp) +6% * Strong underlying growth across health & hygiene boosted by higher incidence
STOCKS NEWS EUROPE-Citi adds Reckitt to focus list, drops Danone
Reckitt Benckiser ascends to Citi's European focus list, replacing Danone, with the bank seeing the consumer health company receiving revenue upgrades and continuing its recent run of outperformance.
Reckitt loses U.S. bid to block generic heroin addict drug
LONDON - U.S. regulators approved two generic versions of Reckitt Benckiser's heroin addiction drug and rejected its bid to block rival products on the grounds that stricter packaging rules were needed to protect children.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$125.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
